A 51-year-old lady presented with episodic discoloration of lower extremities associated with severe pain of 2 years\' duration. She was a nonsmoker, nondiabetic, and normotensive. On examination, she had gangrene involving the left great toe \[[Figure 1](#F1){ref-type="fig"}\]. Evaluation revealed hepatitis C virus (HCV) RNA copies -- 1.4 million copies/mL, genotype -- 3, cryoglobulins -- present, rheumatoid factor -- positive and thrombocytopenia. Color Doppler involving lower limb vessels and two-dimensional echocardiography were normal. Histopathology of the skin showed fibrinoid deposits and thrombus formation in dermal capillaries without active vasculitis. Diagnosis of HCV-associated cryoglobulinemic vasculitis was made. She was treated with tablet sofosbuvir 400 mg and daclatasvir 60 mg once a day along with tablet prednisolone 40 mg once a day. She responded favorably to treatment, and review at 3 months showed resolution of skin lesions \[[Figure 2](#F2){ref-type="fig"}\].

![Gangrene involving the left great toe](IDOJ-9-135-g001){#F1}

![Complete resolution of the gangrene with post-inflammatory pigmentation on the left great toe after 12 weeks](IDOJ-9-135-g002){#F2}

Cryoglobulinemic vasculitis develops in approximately 15% patients with HCV infection, while circulating cryoglobulins are detected in 40--60% of the patients.\[[@ref1]\] Viral clearance is important for the treatment of vasculitis as clinical remission is closely linked with viral clearance. Pegylated interferon α with ribavirin with or without rituximab is the standard of care for the management of cryoglobulinemic vasculitis, but 30--40% patients do not respond to this combination.\[[@ref2]\] With the availability of direct-acting antiviral agents, treatment of this condition has changed dramatically.\[[@ref3]\] In an open label multicentre study, sofosobuvir 400 mg per day and daclatasvir 60 mg per day for 12 weeks resulted in complete clinical response in 90% patients.\[[@ref4]\]
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